Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,101
datasets available to search
ShareScore release 0.7.1
Dataset results
2,101 results for “Cohort studies”
Data for: Evaluation of antibody kinetics and durability in health individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): a cross-sectional and cohort study in Zhejiang, China
<p><strong>Background</strong>: Although inactivated COVID-19 vaccines are proven to be safe and effective in the general population, the dynamic response and duration of antibodies after vaccination in the real world should be further assessed.</p> <p><strong>Methods</strong>: We enrolled 1067 volunteers who had been vaccinated with one or two doses of CoronaVac in Zhejiang Province, China. Another 90 healthy adults without previous vaccinations were recruited and vaccinated with three doses of CoronaVac, 28 days and 6 months apart. Serum samples were collected from multiple timepoints and analyzed for specific IgM/IgG and neutralizing antibodies (NAbs) for immunogenicity evaluation. Antibody responses to the Delta and Omicron variants were measured by pseudovirus-based neutralization tests.</p> <p><strong>Results</strong>: Our results revealed that binding antibody IgM peaked 14–28 days after one dose of CoronaVac, while IgG and NAbs peaked approximately 1 month after the second dose and then declined slightly over time. Antibody responses had waned by month 6 after vaccination and became undetectable in the majority of individuals at 12 months. Levels of NAbs to live SARS-CoV-2 were correlated with anti-SARS-CoV-2 IgG and NAbs to pseudovirus, but not IgM. Homologous booster around 6 months after primary vaccination activated anamnestic immunity and raised NAbs 25.5-fold. The neutralized fraction subsequently rose to 36.0% for Delta (p=0.03) and 4.3% for Omicron (p=0.004), and the response rate for Omicron rose from 7.9% (7/89) to 17.8% (16/90).</p> <p><strong>Conclusions</strong>: Two doses of CoronaVac vaccine resulted in limited protection over a short duration. The inactivated vaccine booster can reverse the decrease of antibody levels to prime strain, but it does not elicit potent neutralization against Omicron; therefore, the optimization of booster procedures is vital.</p>
Association Between Change in The Peripheral Biomarkers of Inflammation, Astrocyte Activation, and Neuroprotection at One Week of Critical Illness and Hospital Mortality in Patients with Delirium: A Prospective Cohort Study
<p>Dataset for the following publication: Association Between Change in The Peripheral Biomarkers of Inflammation, Astrocyte Activation, and Neuroprotection at One Week of Critical Illness and Hospital Mortality in Patients with Delirium: A Prospective Cohort Study</p>
Associations of serum uric acid with cardiovascular disease risk factors: a retrospective cohort study in Southeastern China
<p class="MsoNormal"><span>Objective: To evaluate the associations between serum uric acid (SUA) levels and cardiovascular disease (CVDs) risk factors, focusing on potential sex-specific differences.</span></p> <p class="MsoNormal"><span>Design: A retrospective cohort study.</span></p> <p class="MsoNormal"><span>Setting: A large community-based survey was conducted every two years from 2010 to 2018 in Hangzhou, Zhejiang Province, Southeastern China.</span></p> <p class="MsoNormal"><span>Participants: 6119 participants aged 40 years and above who underwent at least three times of physical examinations were enrolled. </span></p> <p class="MsoNormal"><span>Methods: Participants were categorized into four groups (Q1-Q4) based on baseline SUA quartiles within the normal range, with hyperuricemia (HUA) as the fifth group. The Q1 was the reference. By stratifying participants by gender, the relationships between SUA levels and systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), and total cholesterol (TC) were investigated using linear regression models in the generalized estimating equation (GEE). Additionally, the associations of elevated SUA levels and HUA with hypertension, hyperglycemia, and dyslipidemia were correspondingly examined using multivariate logistic regression models.</span></p> <p class="MsoNormal"><span>Results: After adjusting for confounding variables, we found positive associations between SUA levels and SBP, DBP, FBG, and TC in women, and with TC in men (P < 0.01). Likewise, Elevated SUA quartiles and HUA were linked to increased dyslipidemia risk in both sexes, and increased hyperglycemia risk only in women, with HRs (95%CI) of 1.64 (1.05-2.55) and 2.37 (1.47-3.81) in the Q4 and HUA group, respectively. Women with HUA had higher hypertension risk (HR=1.45, 95% CI 1.21-1.73), while no such association was observed in men. Stratified analyses revealed significant associations between elevated SUA levels and CVDs risk factors in postmenopausal and non-obese women.</span></p> <p class="MsoNormal"><span>Conclusions: Elevated SUA levels increase the risk of dyslipidemia in both sexes. SUA levels within normal-range and HUA are positively associated with hyperglycemia and hypertension in postmenopausal women, but not in men.</span></p>
Data from: Novel methods to define invasive procedures at the end-of-life were developed to improve quality of end of life care research: A population-based cohort study in colorectal cancer
<p><strong>Background</strong></p> <p>Understanding the use of invasive procedures (IPs) at the end-of-life (EoL) is important to avoid under- and overtreatment, but epidemiologic analysis is hampered by limited methods to define treatment intent and EoL phase. This study applied novel methods to report IPs at the EoL using a colorectal cancer (CRC) case study.</p> <p><strong>Methods</strong></p> <p>An English population-based cohort of adult patients diagnosed between 2013 and 2015 was used with follow-up to 2018. Procedure intent (curative, non-curative, diagnostic) by cancer site and stage at diagnosis was classified by two surgeons independently. Joinpoint regression modelled weekly rates of IPs for 36 sub-cohorts of patients with incremental survival of 0-36 months. EoL phase was defined by a significant IP rate change before death. Zero-inflated Poisson regression explored associations between IP rates and clinical/sociodemographic variables.</p> <p><strong>Results</strong></p> <p>Of 87,731 patients included, 41,972 (48%) died. 9,492 procedures were classified by intent (interrater agreement 99.8%). Patients received 502,895 IPs (1.39 and 3.36 per person year for survivors and decedents). Joinpoint regression identified significant increases in IPs four weeks before death in those living 3-6 months, and eight weeks before death in those living 7–36 months from diagnosis. 7,908 (18.8%) patients underwent IPs at the EoL, with stoma formation the most common major procedure. Younger age, early-stage disease, men, lower comorbidity, those receiving chemotherapy and living longer from diagnosis were associated with IPs.</p> <p><strong>Conclusions</strong></p> <p>Methods to identify and classify IPs at the EoL were developed and tested within a CRC population. This approach can be now extended and validated to identify potential under- and overtreatment. </p>
Prospective cohort study of a community-based primary care program's effects on pharmacotherapy quality in low-income Peruvians with type 2 diabetes and hypertension
<p>A door-to-door survey was conducted to enumerate all household members by age and sex in a low-income community in Peru. 856 adults 35 years and older were eligible to participate in screening for type 2 diabetes and hypertension. 709 (83%) participated in screening. 130 (18.3%) were diagnosed with hypertension and/or type 2 diabetes of which 109 (84%) participated at program onset and 22 were added later from earlier non-participants in screening or program onset to form the cohort of 131 patients with diabetes and/or hypertension. The primary care program had components of the Chronic Care Model, community health workers, and freely accessible visits and medications. The program operated between September 2011 and May 2014, and consisted of two care periods (separated by a six-month hiatus), first a 10-month home-care period, then a 17-month clinic-care period. The dataset is two files corresponding to two exposures: the 27-month program overall (post- versus pre-) (N=262 observations, 131 pairs with patients as self-controls) and care period (clinic versus home), N=211 (109 home and 102 clinic observations, >131 because 80 patients participated in both care periods). Exposures were evaluated for their effects on guidelines-based pharmacotherapy standards: hypoglycemic and antihypertensive medications, low-dose aspirin, and first-line angiotensin converting enzyme inhibitor (ACEi) treatment of diabetes with elevated blood pressure.</p>
A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform
ClinicalTrials.gov study NCT03737149. IPD Sharing: NO. Countries: 4. Publications: 1.
TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta
ClinicalTrials.gov study NCT01997892. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)
ClinicalTrials.gov study NCT02202616. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Prospective Multicenter Cohort Study Evaluating the Incidence and Risk Factors for Problem Gambling Among Young Adults With First-episode Psychosis
ClinicalTrials.gov study NCT05686772. IPD Sharing: NO. Countries: 1. Publications: 7.
The Correlation Between Obstructive Sleep Apnea-Related Nocturnal Hypoxemia Parameters and Coronary Microvascular Dysfunction: A Prospective Cohort Study (SLEEP-CMD)
ClinicalTrials.gov study NCT07315399. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
ClinicalTrials.gov study NCT01876511. IPD Sharing: NO. Countries: 1. Publications: 2.
Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study
ClinicalTrials.gov study NCT07253974. IPD Sharing: YES. Countries: 1. Publications: 14.
Clinical Evaluation and Intervention of Developmental Behavioral Diseases Based on Multicenter Cohort Study(CEIDBDBMCS)
ClinicalTrials.gov study NCT06025890. IPD Sharing: NO. Countries: 1. Publications: 5.
PREDICT-H Study: Prospective Research on Essential Determinants Influencing Complication Trends in Hypospadias - a Landmark Prospective Multicenter Cohort Study Aimed at Improving Outcome Prediction i
ClinicalTrials.gov study NCT07017842. IPD Sharing: YES. Countries: 1. Publications: 5.
Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Investigational Device Exemption Cohort
ClinicalTrials.gov study NCT00740870. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort
ClinicalTrials.gov study NCT00824850. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
ClinicalTrials.gov study NCT02067663. IPD Sharing: NO. Countries: 1. Publications: 32.
Safe Kidney Care Cohort Study
ClinicalTrials.gov study NCT01407367. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study
ClinicalTrials.gov study NCT01360762. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Iron Deficiency Anemia Among Chinese Pregnant Women: a Multi-center Prospective Cohort Study
ClinicalTrials.gov study NCT03961074. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.